Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
171.31
+3.96 (2.37%)
Oct 6, 2025, 11:09 AM EDT - Market open
Natera Employees
Natera had 4,434 employees as of December 31, 2024. The number of employees increased by 1,141 or 34.65% compared to the previous year.
Employees
4,434
Change (1Y)
1,141
Growth (1Y)
34.65%
Revenue / Employee
$442,997
Profits / Employee
-$57,113
Market Cap
23.51B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
Dec 31, 2023 | 3,293 | 275 | 9.11% |
Dec 31, 2022 | 3,018 | 348 | 13.03% |
Dec 31, 2021 | 2,670 | 855 | 47.11% |
Dec 31, 2020 | 1,815 | 776 | 74.69% |
Dec 31, 2019 | 1,039 | 64 | 6.56% |
Dec 31, 2018 | 975 | 82 | 9.18% |
Dec 31, 2017 | 893 | 41 | 4.81% |
Dec 31, 2016 | 852 | 136 | 18.99% |
Dec 31, 2015 | 716 | 42 | 6.23% |
Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTRA News
- 5 days ago - Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT - Business Wire
- 6 days ago - Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer - Business Wire
- 7 days ago - Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Business Wire
- 12 days ago - Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Can Natera Stock Reach $500? - Forbes
- 25 days ago - Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability - Seeking Alpha
- 5 weeks ago - Natera Provides Update on Patent Litigation with NeoGenomics - Business Wire